Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.30 |
| ▸ | JAK1 | P23458 | 2/20 | 0.30 |
| ▸ | TYK2 | P29597 | 2/20 | 0.30 |
| ▸ | JAK3 | P52333 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8048336 | 0.73 | CASP1 (0.32) | — | |
| SCHEMBL8052653 | 0.72 | — | — | |
| SCHEMBL8048758 | 0.69 | NOS1 (0.38) | — | |
| SCHEMBL14433577 | 0.66 | SMN1; SMN2 (0.43) | MEN1POLBGAAKMT2A | |
| SCHEMBL9488754 | 0.65 | HRH2 (0.35) | — | |
| SCHEMBL21409728 | 0.64 | MEN1 (0.56) | MEN1POLBGAAKMT2A | |
| SCHEMBL8052575 | 0.63 | PDE10A (0.45) | GAA | |
| SCHEMBL7193572 | 0.63 | PDE10A (0.45) | GAA | |
| SCHEMBL900460 | 0.63 | MEN1 (0.66) | MEN1POLBGAAKMT2AJAK2 | |
| SCHEMBL21409740 | 0.62 | MEN1 (0.41) | MEN1POLBGAAKMT2AJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6150362-A | ADMINISTERING 1,3,5-SUBSTITUTED TRIAZINE COMPOUNDS TO THE PATIENT SUFFERING FROM ANGIOGENIC DISEASES | ABBVIE INC. | 2000-11-21 | — | — | US | claimed |
| EP-1037886-A1 | TRIAZINE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2000-09-27 | — | — | EP | claimed |
| WO-1999031088-A1 | TRIAZINE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-06-24 | — | — | WO | claimed |
| EP-1037886-B1 | TRIAZINE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6288228-B1 | DIAMINOTRIAZINE DERIVATIVES | ABBOTT LABORATORIES | 2001-09-11 | — | — | US | disclosed |
| US-6150362-A | ADMINISTERING 1,3,5-SUBSTITUTED TRIAZINE COMPOUNDS TO THE PATIENT SUFFERING FROM ANGIOGENIC DISEASES | ABBVIE INC. | 2000-11-21 | — | — | US | disclosed |
| EP-1037886-A1 | TRIAZINE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1999031088-A1 | TRIAZINE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0698620-B1 | Method for preparing modified resins and their applications | MITSUI CHEMICALS INC (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0698620-A1 | Method for preparing modified resins and their applications | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1996-02-28 | — | — | EP | disclosed |